|
The combination of disruptive technologies, a proven executive team, and a region ready to support and expedite pre-clinical and clinical development, uniquely positions Orion to rapidly and cost-effectively develop novel therapies for the treatment of severe eye diseases and get them into the clinic where patients desperately need therapeutic innovation.
Further, the SAgA platforms is broadly applicable; autoimmune diseases in which disease specific -antigens have been identified, such as Type-1 Diabetes, neuromyelitis optica, and Myasthenia Gravis |
Soluble Antigen ArraysSoluble Antigen Arrays (SAgAs) are Orion's approach to providing a 'cure' to patients suffering from autoimmune disease. SAgAs can mimic peripheral tolerance through multivalent display of one or more disease specific antigen signals along a flexible polymer. This provides specific interaction with immune cells and promotes tolerance in patients suffering from diseases like Type-1 Diabetes, neuromyelitis optica, MS, and Graves.
|
ORNx FormlationOrion's ORNx Formulation Technology enhances the availability of poorly water-soluble drugs by dramatically increasing dissolution kinetics while maintaining physical properties such as crystallinity, solubility, and stability. Our first clinical program looks to have a substantial and significant impact on the treatment of autoimmune associated uveitison, diabetic macular edema, and potentially chronic dry eye.
|